Review
doi: 10.1038/nrc2066.
Compressing drug development timelines in oncology using phase '0' trials
Affiliations
- PMID: 17251919
- DOI: 10.1038/nrc2066
Item in Clipboard
Review
Compressing drug development timelines in oncology using phase '0' trials
Nat Rev Cancer.
2007 Feb.
Free article
Abstract
The optimal evaluation of molecularly targeted anticancer agents requires the integration of pharmacodynamic assays into early clinical investigations. Phase '0' trials conducted under the new Exploratory Investigational New Drug Guidance from the US Food and Drug Administration can provide a platform to establish the feasibility of assays for target modulation in human samples, evaluate biomarkers for drug effects and provide pharmacokinetic data. Phase 0 trials could facilitate rational drug selection, identify therapeutic failures early, and might compress timelines for anticancer drug development. We expect that such trials will become a routine part of early-phase oncological drug development in the future.
Similar articles
-
Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.Mol Interv. 2007 Dec;7(6):325-34. doi: 10.1124/mi.7.6.9. Mol Interv. 2007. PMID: 18199854 Review.
-
Phase 0 clinical trials will overcome stagnation of anticancer drug development?Klin Onkol. 2011;24(2):143-5. Klin Onkol. 2011. PMID: 21638998
-
Phase 0 clinical trials in oncology: a paradigm shift for early drug development?Cancer Chemother Pharmacol. 2009 Mar;63(4):703-9. doi: 10.1007/s00280-008-0789-4. Epub 2008 Jul 10. Cancer Chemother Pharmacol. 2009. PMID: 18615251 Review.
-
Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patient.Clin Cancer Res. 2008 Jun 15;14(12):3658-63. doi: 10.1158/1078-0432.CCR-07-4562. Clin Cancer Res. 2008. PMID: 18559579 Free PMC article.
-
Pharmacodynamic biomarkers for molecular cancer therapeutics.Adv Cancer Res. 2007;96:213-68. doi: 10.1016/S0065-230X(06)96008-4. Adv Cancer Res. 2007. PMID: 17161682 Review.
Cited by
-
Improving survival and limiting toxicity: latest advances in treating human epidermal growth factor receptor 2 overexpressing breast cancer.Ther Adv Med Oncol. 2012 May;4(3):139-47. doi: 10.1177/1758834012440834. Ther Adv Med Oncol. 2012. PMID: 22590487 Free PMC article.
-
Evaluation of two-stage designs of Phase 2 single-arm trials in glioblastoma: a systematic review.BMC Med Res Methodol. 2022 Dec 22;22(1):327. doi: 10.1186/s12874-022-01810-7. BMC Med Res Methodol. 2022. PMID: 36550391 Free PMC article.
-
Phase 0 clinical trials in oncology new drug development.Perspect Clin Res. 2011 Jan;2(1):13-22. doi: 10.4103/2229-3485.76285. Perspect Clin Res. 2011. PMID: 21584177 Free PMC article.
-
Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium.Neuro Oncol. 2008 Aug;10(4):631-42. doi: 10.1215/15228517-2008-021. Epub 2008 Jun 17. Neuro Oncol. 2008. PMID: 18559968 Free PMC article. Review.
-
Potential impact of platelet-to-lymphocyte ratio on prognosis in patients with colorectal cancer: A systematic review and meta-analysis.Front Surg. 2023 Mar 27;10:1139503. doi: 10.3389/fsurg.2023.1139503. eCollection 2023. Front Surg. 2023. PMID: 37051571 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
